Blarcamesine (proposed name: Anavex 2-73) is an investigational, orally available small molecule that acts as a muscarinic agonist and an agonist of the intracellular sigma-1 chaperone protein. It is in development for the treatment of early Alzheimer disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.